@article {Pillay19002220, author = {Prinisha Pillay and Antonia L Wadley and Catherine L Cherry and Alan S Karstaedt and Peter R Kamerman}, title = {HIV-associated sensory neuropathy continues to be a problem in individuals starting tenofovir-based antiretroviral treatment}, elocation-id = {19002220}, year = {2019}, doi = {10.1101/19002220}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {HIV-associated sensory neuropathy (HIV-SN) is a common and often painful neurological condition associated with HIV-infection and its treatment. However, data on the incidence of HIV-SN in neuropathy-free individuals initiating combination antiretroviral therapies (cART) that do not contain the neurotoxic agent stavudine are lacking. We investigated the six-month incidence of HIV-SN in ART na{\"\i}ve individuals initiating tenofovir (TDF)-based cART, and the clinical factors associated with the development of HIV-SN. 120 neuropathy-free and ART na{\"\i}ve individuals initiating cART at a single centre in Johannesburg, South Africa were enrolled. Participants were screened for HIV-SN at study enrolment and then approximately every two-months for a period of approximately six-months. Symptomatic HIV-SN was defined by the presence of at least one symptom (pain/burning, numbness, paraesthesias) and at least two clinical signs (reduced vibration sense, absent ankle reflexes or pin-prick hypoaesthesia). Asymptomatic HIV-SN required at least two clinical signs only. A total of 88\% of the cohort completed three visits within the six-month period. Eleven individuals developed asymptomatic HIV-SN and nine developed symptomatic HIV-SN, giving a six-month cumulative incidence of neuropathy of 140 cases per 1000 patients (95\% CI: 80 - 210) at an incidence rate of 0.37 (95\% CI: 0.2 - 0.5) per person year. Increasing height and active tuberculosis (TB) disease were independently associated with the risk of developing HIV-SN (p \< 0.05). We found that within the first six months of starting cART, incident SN persists in the post-stavudine era, but may be asymptomatic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was supplied by the Medical Faculty Research Endowment Fund of the University of the Witwatersrand. Medical Research Council of South Africa. National Research Foundation Rated Researchers Programme. The authors gratefully acknowledge the contributions of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableStudy participants did not consent to the public release of their data. However, the data are available on request from Peter Kamerman (peter.kamerman@wits.ac.za or peter.kamerman@gmail.com). https://github.com/kamermanpr/hivsn-incidence.git}, URL = {https://www.medrxiv.org/content/early/2019/07/19/19002220}, eprint = {https://www.medrxiv.org/content/early/2019/07/19/19002220.full.pdf}, journal = {medRxiv} }